Nevirapine, given once during labor, either alone or in combination with a short course of zidovudine (AZT) or other antiretroviral medications, significantly reduces the chances that a pregnant woman will pass HIV to her child. A single dose of nevirapine during labor is frequently all that is accessible to pregnant women in resource-limited settings where more complicated and expensive, multidrug treatments may not be available.
The use of single-dose nevirapine has successfully reduced mother-to-infant transmission of HIV, but has also created a terrible dilemma for physicians and patients. Research has shown that 20 to 69 percent of women who take a single dose of nevirapine during labor subsequently develop resistance to the drug -- a situation that may undermine the patients" ability to respond later to nevirapine-containing ART when they may need the treatment to save their lives. Nevirapine is the cornerstone of three-drug ART in most regions of the world. Drug resistance develops as well in a range of the minority of infants who become HIV infected, despite the use of single-dose nevirapine.
Now, a team of researchers led by Shahin Lockman, Assistant Professor in the Department of Immunology and Infectious Diseases at Harvard School of Public Health (HSPH) and at Brigham and Women's Hospital, and Max Essex, chair of the HSPH AIDS Initiative, has conducted a study that suggests a potential solution to this problem. The results may help women who already received a single dose of nevirapine during labor and those who have not yet given birth.
Working within a randomized clinical trial established by the Botswana-HSPH AIDS Initiative Partnership for HIV Research and Education, the team conducted a prospective observational study that included 218 postpartum, HIV-infected women who had received a single dose of nevirapine during labor, in addition to a short course of AZT during pregnancy. Sixty women started nevirapine-based ART within six months of giving birth, and the remaining women began the regimen after that time had passed.
Of the 60 women who started nevirapine-based ART within six months of giving birth, 24 had received a single dose of nevirapine during labor, while 36 had received a placebo. (All of the women in the study were given zidovudine from 34 weeks into their pregnancies through delivery; similar to nevirapine, zidovudine reduces HIV transmission from mother to child.) Of the women in this group who received a single dose of nevirapine during labor, 41.7 percent subsequently experienced treatment failure, or "virologic failure," within a half a year of starting ART -- compared to zero percent among the women in this group who had received placebo during delivery. Similar differences were found at follow-up visits one and two years after ART had started.
In contrast, there were no statistically significant differences in failure rates within the women who delayed ART for six months -- regardless of whether they had received a single dose of nevirapine during labor or not. This group (and additional women who have joined the study since) continues to be followed to ensure that no differences emerge as the women receive treatment over a longer period of time, said Dr. Lockman.
She added that these findings may be explained by the fact that the amount of nevirapine-resistant HIV in the body decreases as time passes from the time of exposure to single-dose nevirapine during labor.
Said Dr. Essex, "These results translate into very clear policy for how to treat AIDS in new mothers who received nevirapine to protect their infants. If you can wait six months to administer nevirapine-based ART, do so. If not, treat only with combinations of drugs that do not contain nevirapine or nevirapine-related drugs. Implementing this policy can improve the health of women who need AIDS treatment."
Treatment response was also measured among 30 infants in the study who received nevirapine-based ART. More than three-quarters of the 15 infants who were exposed to single dose nevirapine as newborns did not respond adequately to the triple-drug treatment (compared with 9.1 percent of the 15 infants without prior nevirapine exposure). While these results raise concerns regarding the use of nevirapine-based ART for infants following single-dose nevirapine exposure, said Dr. Lockman, the group of infants studied was small, and additional data among infants is needed.
Summarized Dr. Lockman, "Women who need combination ART for their own health during pregnancy should absolutely receive combination ART whenever possible. However, single-dose nevirapine remains important in preventing mother-to-child transmission of HIV in many locales where it is still the only intervention available. This study provides some important guidance and measured reassurance regarding the timing and effectiveness of nevirapine-based antiretroviral treatment for the many women with AIDS who previously received single-dose nevirapine in labor."
Christina Roache | EurekAlert!
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences